| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762611186P | 2017-12-28 | 2017-12-28 | |
| PCT/US2018/067856WO2019133809A1 (en) | 2017-12-28 | 2018-12-28 | Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment |
| Publication Number | Publication Date |
|---|---|
| SG11202006200RAtrue SG11202006200RA (en) | 2020-07-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006200RASG11202006200RA (en) | 2017-12-28 | 2018-12-28 | Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment |
| Country | Link |
|---|---|
| US (1) | US11571427B2 (en) |
| EP (1) | EP3731848A4 (en) |
| JP (2) | JP2021508720A (en) |
| KR (1) | KR20200105678A (en) |
| CN (1) | CN111770759A (en) |
| AU (1) | AU2018395291A1 (en) |
| BR (1) | BR112020013285A2 (en) |
| CA (1) | CA3087230A1 (en) |
| IL (1) | IL275692A (en) |
| MX (1) | MX2020006808A (en) |
| SG (1) | SG11202006200RA (en) |
| WO (1) | WO2019133809A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (en) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | Pyrazole derivatives as malt1 inhibitors |
| BR112021016400A2 (en) | 2019-02-22 | 2021-10-13 | Janssen Pharmaceutica N.V. | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DI-HYDROISOQUINOLIN-5-YL)-5-(TRIFLUOROMETHYL.)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H MONOHYDRATE -PYRAZOLE-4-CARBOXAMIDE |
| MA55593A (en) | 2019-04-11 | 2022-02-16 | Janssen Pharmaceutica Nv | PYRIDINE CYCLES CONTAINING DERIVATIVES SERVING AS MALT1 INHIBITORS |
| CN111686111B (en)* | 2020-06-09 | 2023-06-13 | 南方医科大学 | Application of MALT1 protease inhibitor in preparation of non-small cell lung cancer therapeutic drug |
| US20240238419A1 (en)* | 2021-05-07 | 2024-07-18 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Method for constitutive malt1 protease activation |
| WO2025082417A1 (en)* | 2023-10-18 | 2025-04-24 | 苏州沙砾生物科技有限公司 | Cell expressing fusion protein and use thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| DK1478648T3 (en) | 2002-02-01 | 2014-07-28 | Ariad Pharma Inc | PHOSPHORUS RELATIONS AND APPLICATIONS THEREOF |
| US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US9017697B2 (en)* | 2006-10-12 | 2015-04-28 | The University Of Queensland | Compositions and methods for modulating immune responses |
| CN102131828B (en) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | Antibody against human programmed death receptor PD-1 |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| PT4209510T (en) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| JP2013532153A (en) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2916656B1 (en)* | 2012-11-09 | 2017-10-25 | Cornell University | Small molecule inhibitors of malt1 |
| ES2909438T3 (en)* | 2013-06-26 | 2022-05-06 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Enantiomer (S) of mepacine as a paracaspase (MALT1) inhibitor to treat cancer |
| CN106170489B (en) | 2014-05-28 | 2019-05-03 | 诺华股份有限公司 | Novel pyrazolopyrimidine derivatives and their use as MALT1 inhibitors |
| DE102015210224A1 (en) | 2015-06-02 | 2016-12-08 | Universitätsklinikum Hamburg-Eppendorf | NEW ACTIVE FOR THE TREATMENT OF CANCER |
| WO2017008046A1 (en)* | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| JP6989505B2 (en) | 2015-08-28 | 2022-01-05 | コーネル ユニヴァーシティー | MALT1 inhibitor and its use |
| WO2017081641A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| CA3030949A1 (en) | 2016-07-29 | 2018-02-01 | Toray Industries, Inc. | Guanidine derivative and medical use thereof |
| SG11201900745VA (en) | 2016-07-29 | 2019-02-27 | Lupin Ltd | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| US10689366B2 (en) | 2016-11-01 | 2020-06-23 | Cornell University | Compounds for MALT1 degredation |
| TWI795381B (en) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | Pyrazole derivatives as malt1 inhibitors |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| Publication number | Publication date |
|---|---|
| KR20200105678A (en) | 2020-09-08 |
| BR112020013285A2 (en) | 2020-12-01 |
| JP2024028924A (en) | 2024-03-05 |
| MX2020006808A (en) | 2020-12-11 |
| JP2021508720A (en) | 2021-03-11 |
| CA3087230A1 (en) | 2019-07-04 |
| WO2019133809A1 (en) | 2019-07-04 |
| AU2018395291A1 (en) | 2020-07-30 |
| IL275692A (en) | 2020-08-31 |
| EP3731848A1 (en) | 2020-11-04 |
| EP3731848A4 (en) | 2021-12-15 |
| CN111770759A (en) | 2020-10-13 |
| US20210052596A1 (en) | 2021-02-25 |
| US11571427B2 (en) | 2023-02-07 |
| Publication | Publication Date | Title |
|---|---|---|
| IL275692A (en) | Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment | |
| Upson et al. | Where are all the female geniuses? | |
| SG11202103832SA (en) | Anti-cd33 immune cell cancer therapy | |
| GB201322725D0 (en) | Cancer therapy | |
| GB201607708D0 (en) | USB power delivery | |
| SG10201913730RA (en) | Cancer therapy | |
| PL3511004T3 (en) | Combined preparations for the treatment of cancer | |
| SG11201507847UA (en) | Cancer therapy | |
| PT3053578T (en) | Combination cancer therapy using azabicyclo compound | |
| EP2994155A4 (en) | Targeting the egfr-sglt1 interaction for cancer therapy | |
| IL253779A0 (en) | Compounds with anti-tumoral activity | |
| EP2961412A4 (en) | Cancer therapy | |
| SG2013072863A (en) | Roulette wheel with smart cover | |
| GB2561032B (en) | Castor wheel cover | |
| PL3016661T3 (en) | Inhibition of the synthesis of beta-app or of the activity of the a beta peptide in the choroid plexus | |
| IL271989A (en) | Targeting the hdac2-sp3 complex to enhance synaptic function | |
| GB2514578B (en) | Lipstick case | |
| GB201308039D0 (en) | Photodynamic therapy | |
| Tracy | PRIDE & POWER | |
| GB201518731D0 (en) | Tumour Therapy | |
| UA75013U (en) | use of dense extract of burdock root or leaves as prostate protective agent | |
| Harmon | The social genius of animals | |
| Yeigh | Honoring Our Past While Preparing Our Future | |
| HOUT et al. | To See or Not to See | |
| Maurel | Victor Maurel: ses idées-son art |